Lobe Sciences Ltd.

LOBE

CA53946V2066

Pharmaceuticals

Delayed Canadian Securities Exchange Other stock markets 11:00:13 16/07/2024 pm IST			5-day change	1st Jan Change
0.02 ^CAD	0.00%		0.00%	-20.00%

04/06	Lobe Sciences Ltd. announced that it has received CAD 0.5 million in funding from Quality Chemical Laboratories, LLC, Clearway Global Llc	CI
03/06	Lobe Sciences Ltd. Announces Appointment of Wesley Ramjeet to the Board of Directors	CI

Green Star Biosciences Inc. announced that it has received $0.25 million in funding

January 18, 2019

On January 18, 2019, Green Star Biosciences Inc. closed the transaction. The transaction included participation from 3 investors.

Latest news about Lobe Sciences Ltd.

Lobe Sciences Ltd. announced that it has received CAD 0.5 million in funding from Quality Chemical Laboratories, LLC, Clearway Global Llc	04/06	CI
Lobe Sciences Ltd. Announces Appointment of Wesley Ramjeet to the Board of Directors	03/06	CI
Lobe Sciences Ltd. Announces Frederick D. Sancilio Ph.D. to Join Board of Directors	31/05	CI
Harry Jacobson to Join the Board of Directors of Lobe Sciences Ltd	30/05	CI
Lobe Sciences Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended February 29, 2024	30/04	CI
Lobe Sciences Ltd. Reports Earnings Results for the Full Year Ended August 31, 2023	15/02	CI
Lobe Sciences Provides Update on L-130 Clinical Program	07/12	MT
Lobe Sciences Ltd. Provides Update on L-130 Clinical Program	07/12	CI
Lobe Sciences Provides Update on L-130 Oral Psilocin Compound	05/12	MT
Lobe Sciences Appoints CFO	18/23/18	MT
Lobe Sciences Ltd. Appoints Mathew Lee as Chief Financial Officer	18/23/18	CI
Lobe Sciences Amends Terms of Altemia Share Purchase Agreement	15/23/15	MT
Lobe Sciences Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended May 31, 2023	02/23/02	CI
Lobe Sciences Ltd. Initiates Phase 1 Clinical Trial of L-130	27/23/27	CI
Lobe Sciences Appoints Baxter Phillips as Chief Operating Officer	07/23/07	CI
Lobe Sciences Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended February 28, 2023	28/23/28	CI
Lobe Sciences Ltd. completed the acquisition of Altemia and Company, LLC from Sancilio, LLC, PBHC1, LLC and Bruce Crawford for CAD 3.8 million.	18/23/18	CI
Lobe Sciences Ltd. signed a share purchase agreement to acquire Altemia and Company, LLC for CAD 3.8 million.	18/23/18	CI
Lobe Sciences Ltd. announced that it expects to receive $0.25 million in funding	10/23/10	CI
Lobe Sciences Ltd. Reports Earnings Results for the First Quarter Ended November 30, 2022	31/23/31	CI
Lobe Sciences Ltd. Auditor Raises 'Going Concern' Doubt	22/22/22	CI
Lobe Sciences Ltd. Reports Earnings Results for the Full Year Ended August 31, 2022	22/22/22	CI
Lobe Sciences Ltd. Provides an Update to Clinical Development Plans for Its Proprietary Psilocin Product, L-130	30/22/30	CI
Lobe Sciences Ltd. Appoints Baxter F. Phillips III to the Board of Directors	05/22/05	CI
Lobe Sciences Ltd. Announces Resignation of Jonathan Gilbert of Board Chairman	04/22/04	CI

Lobe Sciences Ltd. is a Canada-based biopharmaceutical company focused on developing patient-friendly, practical psychedelic medicines. The Company, through collaborations with partners, is engaged in drug research and development using sub-hallucinatory doses of proprietary compounds to treat Orphan diseases. Its new chemical entities, L-130 and L-131, are being developed to address unmet medical needs such as Chronic Cluster Headaches and other Orphan diseases. In addition, the Company is commercializing Altemia, for the treatment of patients diagnosed with Sickle Cell Disease. Its subsidiaries include Eleusian Biosciences Corp., Lobe Sciences Australia Pty Ltd. and Altemia & Company, LLC.

Sector

Pharmaceuticals

Calendar

22/07/2024 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Chiffre d''affaires - Rate of surprise

Company calendar

Sector Alternative Medicine

	1st Jan change	Capi.
LOBE SCIENCES LTD.	-20.00%	2.51M
DONG-E-E-JIAO CO.,LTD.	+7.30%	4.81B
SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.	-31.08%	3.6B
TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED	-0.71%	3.09B
TASLY PHARMACEUTICAL GROUP CO., LTD	-24.32%	2.62B
SHANDONG BUCHANG PHARMACEUTICALS CO., LTD.	-11.35%	2.27B
HENAN LINGRUI PHARMACEUTICAL CO., LTD.	+34.19%	1.82B
ZHEJIANG JOLLY PHARMACEUTICAL CO.,LTD	+33.49%	1.41B
TIBET CHEEZHENG TIBETAN MEDICINE CO., LTD.	-15.07%	1.38B
PT INDUSTRI JAMU DAN FARMASI SIDO MUNCUL TBK	+40.95%	1.37B

Alternative Medicine

Lobe Sciences Ltd.

Equities

LOBE

CA53946V2066

Pharmaceuticals

Green Star Biosciences Inc. announced that it has received $0.25 million in funding

Latest news about Lobe Sciences Ltd.

Chart Lobe Sciences Ltd.

Company Profile

Income Statement Evolution

Chiffre d''affaires - Rate of surprise

Sector Alternative Medicine